I went to the presentation and can appreciate your sentiments....

I went to the presentation and can appreciate your sentiments. Tony is definitely across the technical aspects of the technology and the business however if the purpose of these presentations is to attract new investors a more charismatic salesman could be used.

As for the rest of the presentation it was much the same as previous years however Tony did stress that the focus is moving from trials to commercialisation. He stated CE Mark is expected in the next couple of months. Its been with them for almost 4 months and considering it utilises the outstanding Aus Results it should be the first regulatory approval.

The Australian Adult results are still expected in the next 2 weeks.

And the FDA submission for children for the three illnesses is still expected in the next 2 weeks.

The sleep apnea time frame does appear to have moved to 1H 2019. There was no comment on this. I for one don't mind as the focus should clearly be getting the resappdx product to market, which they are focused on doing.

I was unfortunately unable to stick around and ask questions so if anyone else has anything else to add that'd be greatly appreciated.

Exciting times ahead moving this to commercialisation.